Apreo Health Announces First Patient Treated in BREATHE-3, Pivotal Clinical Trial of Company’s BREATHE Airway Scaffold
MENLO PARK, Calif.--(BUSINESS WIRE)--Apreo Health, a clinical-stage medical device company pioneering a novel, tissue-sparing approach for treating severe emphysema, today announced that the first patient has been treated in its pivotal clinical trial, BREATHE-3 (Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung—Study 3). The trial is evaluating the safety and efficacy of the Apreo BREATHE Airway Scaffold, a bronchoscopically delivered, self-expanding implant designed to
Related Questions
What are the primary and secondary endpoints of the BREATHE-3 trial, and how do they compare to industry standards?
When are the interim and final results of the BREATHE-3 trial expected to be released?
How might the initiation of patient treatment in BREATHE-3 affect Apreo Health's short‑term cash burn and runway?
What is the projected timeline for potential FDA clearance or CE Mark approval based on BREATHE-3 outcomes?
How does the BREATHE Airway Scaffold's mechanism of action differ from existing bronchoscopic emphysema therapies?
What is the size of the target market for the BREATHE Airway Scaffold and the expected market share for Apreo Health?
Are there any partnership or licensing agreements tied to the BREATHE-3 trial results that could influence the stock price?
What are the potential risks or failure points identified for the BREATHE-3 trial that could impact investor sentiment?
How will the enrollment rate and total patient cohort size for BREATHE-3 compare to Apreo's previous trials (BREATHE-1, BREATHE-2)?
What is the anticipated pricing strategy for the BREATHE Airway Scaffold upon potential market launch?